Your browser doesn't support javascript.
loading
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy.
Bao, Yi; Oguz, Gokce; Lee, Wee Chyan; Lee, Puay Leng; Ghosh, Kakaly; Li, Jiayao; Wang, Panpan; Lobie, Peter E; Ehmsen, Sidse; Ditzel, Henrik J; Wong, Andrea; Tan, Ern Yu; Lee, Soo Chin; Yu, Qiang.
Afiliación
  • Bao Y; Cancer Science Institute of Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore.
  • Oguz G; Cancer Precision Medicine, Genome Institute of Singapore, Agency for Science, Technology, and Research, Biopolis, Singapore, 138672, Singapore.
  • Lee WC; Cancer Precision Medicine, Genome Institute of Singapore, Agency for Science, Technology, and Research, Biopolis, Singapore, 138672, Singapore.
  • Lee PL; Cancer Precision Medicine, Genome Institute of Singapore, Agency for Science, Technology, and Research, Biopolis, Singapore, 138672, Singapore.
  • Ghosh K; Cancer Precision Medicine, Genome Institute of Singapore, Agency for Science, Technology, and Research, Biopolis, Singapore, 138672, Singapore.
  • Li J; Cancer Precision Medicine, Genome Institute of Singapore, Agency for Science, Technology, and Research, Biopolis, Singapore, 138672, Singapore.
  • Wang P; Cancer Research Institute, Jinan University, Guangzhou, China.
  • Lobie PE; Cancer Research Institute, Jinan University, Guangzhou, China.
  • Ehmsen S; Cancer Science Institute of Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore.
  • Ditzel HJ; Tsinghua-Berkeley Shenzhen Institute, Guangdong Province and Shenzhen Bay Laboratory, Tsinghua University, Shenzhen, Guangdong Province, China.
  • Wong A; Department of Oncology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, 5230, Odense, Denmark.
  • Tan EY; Department of Oncology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, 5230, Odense, Denmark.
  • Lee SC; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, 5230, Odense, Denmark.
  • Yu Q; Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, 119047, Singapore.
Nat Commun ; 11(1): 5878, 2020 11 18.
Article en En | MEDLINE | ID: mdl-33208750
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Proteína Fosfatasa 2 / Proteína Potenciadora del Homólogo Zeste 2 / Proteínas del Tejido Nervioso / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2020 Tipo del documento: Article País de afiliación: Singapur
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Proteína Fosfatasa 2 / Proteína Potenciadora del Homólogo Zeste 2 / Proteínas del Tejido Nervioso / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2020 Tipo del documento: Article País de afiliación: Singapur